Clinical Trial Update: A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating itacitinib with low-dose ruxolitinib or itacitinib alone after ruxolitinib in myelofibrosis; trial completed with results posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myeloproliferative Neoplasms

Drugs mentioned

• Itacitinib (itacitinib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: MPN (Myeloproliferative Neoplasms) | Phase 2 | Status: COMPLETED | Results posted: 2021-07-02